data_1nmg_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 1nmg _Structure_validation_residue.Date_analyzed 2016-10-06 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.438 -0.579 . . . . 3.28 109.438 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' LEU . . . . . 0.602 ' C ' ' CD1' ' A' ' 2' ' ' LEU . 0.0 OUTLIER -140.78 178.03 7.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.757 -0.589 . . . . 1.37 110.265 179.786 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' GLU . . . . . 0.463 ' HG2' ' O ' ' A' ' 47' ' ' VAL . 0.1 OUTLIER -113.79 145.88 40.76 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.178 -0.951 . . . . 2.04 110.62 -178.644 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' GLY . . . . . 0.479 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -123.63 163.74 17.08 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.821 -1.312 . . . . 0.49 109.821 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 84.7 mttt -137.06 124.62 22.2 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 121.377 -1.073 . . . . 3.13 109.543 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.501 HG12 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -46.29 135.33 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.356 0 CA-C-O 122.5 1.143 . . . . 1.14 113.597 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.55 -32.94 13.24 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 103.66 -2.718 . . . . 2.46 103.66 172.413 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' TRP . . . . . 0.631 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 24.2 p-90 177.45 148.76 0.15 Allowed 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 106.521 -1.659 . . . . 0.43 106.521 177.734 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' PHE . . . . . 0.517 ' CZ ' HD12 ' A' ' 41' ' ' LEU . 0.5 OUTLIER -120.1 143.42 48.15 Favored 'General case' 0 N--CA 1.506 2.368 0 O-C-N 120.629 -1.295 . . . . 2.33 109.745 178.976 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' ASN . . . . . 0.631 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 3.8 m-20 -127.17 45.42 2.71 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 107.042 -1.466 . . . . 1.92 107.042 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 p -45.55 -46.25 13.98 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 115.861 -0.609 . . . . 1.44 109.808 -178.832 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -60.54 -45.29 94.44 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.775 -0.578 . . . . 2.08 109.791 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' LYS . . . . . 0.517 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 7.9 mptt -70.75 -1.2 10.72 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.883 -0.511 . . . . 2.15 110.612 179.613 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLY . . . . . 0.472 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 93.72 20.28 32.05 Favored Glycine 0 N--CA 1.497 2.739 0 O-C-N 121.212 -0.93 . . . . 0.69 113.049 178.174 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.501 ' HE1' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER 178.17 159.9 0.53 Allowed 'General case' 0 N--CA 1.514 2.725 0 CA-C-N 120.318 2.059 . . . . 2.4 112.161 179.457 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.444 ' O ' HG21 ' A' ' 28' ' ' VAL . . . -143.56 154.19 25.37 Favored Glycine 0 N--CA 1.505 3.262 0 N-CA-C 108.236 -1.946 . . . . 0.36 108.236 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PHE . . . . . 0.488 ' HB2' ' CE2' ' A' ' 8' ' ' TRP . 4.1 m-85 -115.89 138.46 51.15 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.29 -1.712 . . . . 2.19 110.253 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.504 ' O ' ' HA ' ' A' ' 25' ' ' ASP . 1.6 mt -106.49 153.98 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 N-CA-C 106.872 -1.529 . . . . 1.06 106.872 178.231 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' GLU . . . . . 0.472 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 12.7 tt0 -127.92 134.17 49.31 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.22 -1.03 . . . . 1.97 108.22 177.95 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' VAL . . . . . 0.56 HG12 ' HB2' ' A' ' 23' ' ' GLN . 9.0 p -136.06 140.15 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.136 0 C-N-CA 118.185 -1.406 . . . . 1.13 112.029 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -63.73 137.45 58.07 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 115.136 -0.938 . . . . 2.71 109.647 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.2 -18.34 37.29 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.302 -1.519 . . . . 0.42 109.302 -178.756 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' GLN . . . . . 0.56 ' HB2' HG12 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -132.95 -172.86 3.03 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.639 -0.918 . . . . 2.87 108.788 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.59 -166.95 1.37 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 122.07 0.938 . . . . 1.61 110.802 -179.21 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.504 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.8 p-10 -73.32 107.19 5.49 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.668 -0.696 . . . . 2.2 110.072 178.968 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.56 HG12 ' HB1' ' A' ' 60' ' ' ALA . 2.4 t -67.26 132.2 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 120.856 -1.152 . . . . 1.11 110.849 178.306 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' PHE . . . . . 0.507 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 1.9 t80 -71.22 136.72 48.16 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.959 -1.497 . . . . 2.3 106.959 177.008 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' VAL . . . . . 0.529 ' HB ' ' CD1' ' A' ' 33' ' ' ILE . 1.5 m -139.11 147.87 24.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.919 -1.113 . . . . 2.01 110.899 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' HIS . . . . . 0.435 ' O ' HD11 ' A' ' 33' ' ' ILE . 15.3 t-160 -134.77 150.6 50.57 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 107.533 -1.284 . . . . 2.07 107.533 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' PHE . . . . . 0.478 ' O ' ' HG3' ' A' ' 34' ' ' GLN . 38.4 p90 -72.18 22.62 0.05 Allowed 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.938 -1.101 . . . . 2.35 110.974 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' SER . . . . . 0.426 ' H ' ' C ' ' A' ' 29' ' ' HIS . 1.1 m -113.72 -34.18 5.58 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.815 -1.178 . . . . 1.88 109.625 179.386 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ALA . . . . . . . . . . . . . . . -91.31 -49.87 6.12 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.444 -0.785 . . . . 1.07 109.848 -179.981 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ILE . . . . . 0.601 ' CG1' ' HB ' ' A' ' 63' ' ' VAL . 1.3 mt -71.95 -1.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.353 0 O-C-N 121.475 -0.765 . . . . 2.07 109.705 178.922 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLN . . . . . 0.478 ' HG3' ' O ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -67.47 -167.46 0.06 Allowed 'General case' 0 N--CA 1.497 1.883 0 CA-C-O 121.714 0.769 . . . . 4.49 111.735 -178.494 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.5 -168.65 35.56 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.394 -1.482 . . . . 2.74 109.394 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -50.45 118.59 3.12 Favored 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.565 -0.962 . . . . 5.7 110.658 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.69 152.71 24.03 Favored Glycine 0 N--CA 1.499 2.87 0 N-CA-C 110.081 -1.207 . . . . 3.98 110.081 179.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -71.12 122.0 19.33 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.368 -1.078 . . . . 5.84 109.05 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.8 mmpp? -112.66 168.55 9.57 Favored 'General case' 0 N--CA 1.501 2.107 0 CA-C-O 122.24 1.019 . . . . 5.3 112.566 -178.559 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' THR . . . . . 0.416 ' C ' ' HG ' ' A' ' 41' ' ' LEU . 1.4 t -143.51 173.53 11.55 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 106.914 -1.513 . . . . 3.39 106.914 177.616 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.517 HD12 ' CZ ' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -150.91 164.48 36.22 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.65 -1.281 . . . . 4.32 112.29 -178.294 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -120.58 179.37 4.35 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.012 -1.107 . . . . 3.69 108.012 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.0 tm-20 -73.5 147.2 44.28 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.089 -1.007 . . . . 3.92 108.496 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 95.36 -1.79 64.75 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 110.481 -1.048 . . . . 1.36 110.481 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' GLN . . . . . 0.472 ' CD ' ' HB3' ' A' ' 41' ' ' LEU . 22.6 tt0 -74.4 118.58 17.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.346 -1.091 . . . . 4.02 110.454 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -91.23 130.35 37.12 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.364 -0.976 . . . . 1.28 108.364 178.495 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.529 HG11 ' HA ' ' A' ' 65' ' ' LYS . 26.8 m -124.61 163.81 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.303 -0.873 . . . . 1.13 110.337 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.3 p -116.1 131.18 57.01 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.003 -0.74 . . . . 1.15 109.003 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' PHE . . . . . 0.628 ' CE1' HG13 ' A' ' 51' ' ' ILE . 17.1 p90 -156.49 -176.82 6.18 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.748 0.785 . . . . 2.07 110.329 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.46 92.91 3.59 Favored 'General case' 0 N--CA 1.486 1.368 0 N-CA-C 109.165 -0.679 . . . . 2.53 109.165 179.254 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ILE . . . . . 0.628 HG13 ' CE1' ' A' ' 49' ' ' PHE . 11.9 mt -61.45 135.53 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 CA-C-O 122.105 0.955 . . . . 1.79 110.468 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 14.6 m -118.88 -174.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 106.984 -1.487 . . . . 1.07 106.984 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -122.64 114.16 20.22 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.136 -0.977 . . . . 2.54 109.39 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.96 175.75 18.3 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.829 -1.309 . . . . 0.38 109.829 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -38.38 -51.6 1.54 Allowed 'General case' 0 N--CA 1.512 2.659 0 N-CA-C 113.354 0.872 . . . . 2.3 113.354 -178.739 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 11.83 2.06 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 119.967 -1.708 . . . . 4.61 112.391 -178.782 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.64 -171.41 19.21 Favored Glycine 0 N--CA 1.501 2.99 0 O-C-N 120.539 -1.351 . . . . 0.51 110.479 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' PRO . . . . . 0.549 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.6 Cg_endo -63.77 139.65 69.96 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 121.888 1.726 . . . . 0.37 110.093 178.829 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' GLN . . . . . 0.507 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.6 mt-30 -156.37 145.61 20.56 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.628 -0.67 . . . . 1.73 111.237 -178.981 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.56 ' HB1' HG12 ' A' ' 26' ' ' VAL . . . -79.16 159.73 27.28 Favored 'General case' 0 N--CA 1.502 2.135 0 N-CA-C 107.544 -1.28 . . . . 1.09 107.544 177.077 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' ALA . . . . . . . . . . . . . . . -134.26 -43.72 0.78 Allowed 'General case' 0 N--CA 1.517 2.882 0 O-C-N 120.743 -1.223 . . . . 1.07 112.567 -176.428 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -121.64 54.78 1.12 Allowed 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 106.695 -1.594 . . . . 2.58 106.695 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' VAL . . . . . 0.601 ' HB ' ' CG1' ' A' ' 33' ' ' ILE . 11.8 t -70.5 165.37 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.515 -0.766 . . . . 1.06 109.781 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER -154.18 146.85 24.2 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.466 -0.939 . . . . 1.2 108.466 178.518 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' LYS . . . . . 0.529 ' HA ' HG11 ' A' ' 47' ' ' VAL . 4.0 ptpt -60.83 135.93 57.92 Favored 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.403 -0.811 . . . . 3.85 110.21 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -78.87 124.68 28.47 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.419 -0.801 . . . . 2.38 109.793 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 118.499 -0.762 . . . . 2.64 109.627 179.922 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.438 -0.579 . . . . 2.78 109.438 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' LEU . . . . . 1.019 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.78 178.03 7.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.757 -0.589 . . . . 0.64 110.265 179.786 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 3' ' ' GLU . . . . . 0.533 ' OE1' ' HB1' ' A' ' 46' ' ' ALA . 0.1 OUTLIER -113.79 145.88 40.76 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.178 -0.951 . . . . 2.04 110.62 -178.644 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' GLY . . . . . 0.488 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -123.63 163.74 17.08 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.821 -1.312 . . . . 0.37 109.821 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 84.7 mttt -137.06 124.62 22.2 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 121.377 -1.073 . . . . 2.62 109.543 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -46.29 135.33 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.356 0 CA-C-O 122.5 1.143 . . . . 0.4 113.597 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.55 -32.94 13.24 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 103.66 -2.718 . . . . 1.93 103.66 172.413 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' TRP . . . . . 0.639 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 24.2 p-90 177.45 148.76 0.15 Allowed 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 106.521 -1.659 . . . . 0.38 106.521 177.734 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' PHE . . . . . 0.604 ' CD2' HD13 ' A' ' 41' ' ' LEU . 0.5 OUTLIER -120.1 143.42 48.15 Favored 'General case' 0 N--CA 1.506 2.368 0 O-C-N 120.629 -1.295 . . . . 1.52 109.745 178.976 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 10' ' ' ASN . . . . . 0.639 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 3.8 m-20 -127.17 45.42 2.71 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 107.042 -1.466 . . . . 1.72 107.042 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 p -45.55 -46.25 13.98 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 115.861 -0.609 . . . . 1.07 109.808 -178.832 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -60.54 -45.29 94.44 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.775 -0.578 . . . . 2.08 109.791 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' LYS . . . . . 0.546 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 7.9 mptt -70.75 -1.2 10.72 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.883 -0.511 . . . . 1.51 110.612 179.613 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLY . . . . . 0.467 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 93.72 20.28 32.05 Favored Glycine 0 N--CA 1.497 2.739 0 O-C-N 121.212 -0.93 . . . . 0.49 113.049 178.174 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.524 ' HE1' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER 178.17 159.9 0.53 Allowed 'General case' 0 N--CA 1.514 2.725 0 CA-C-N 120.318 2.059 . . . . 1.55 112.161 179.457 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.592 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -143.56 154.19 25.37 Favored Glycine 0 N--CA 1.505 3.262 0 N-CA-C 108.236 -1.946 . . . . 0.27 108.236 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PHE . . . . . 0.511 ' HB2' ' CE2' ' A' ' 8' ' ' TRP . 4.1 m-85 -115.89 138.46 51.15 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.29 -1.712 . . . . 1.29 110.253 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.717 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.6 mt -106.49 153.98 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 N-CA-C 106.872 -1.529 . . . . 0.3 106.872 178.231 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 19' ' ' GLU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 12.7 tt0 -127.92 134.17 49.31 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.22 -1.03 . . . . 1.97 108.22 177.95 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' VAL . . . . . 0.601 HG13 ' HB2' ' A' ' 23' ' ' GLN . 9.0 p -136.06 140.15 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.136 0 C-N-CA 118.185 -1.406 . . . . 0.32 112.029 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -63.73 137.45 58.07 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 115.136 -0.938 . . . . 2.71 109.647 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.2 -18.34 37.29 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.302 -1.519 . . . . 0.42 109.302 -178.756 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' GLN . . . . . 0.601 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -132.95 -172.86 3.03 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.639 -0.918 . . . . 2.21 108.788 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.59 -166.95 1.37 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 122.07 0.938 . . . . 1.61 110.802 -179.21 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.8 p-10 -73.32 107.19 5.49 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.668 -0.696 . . . . 2.2 110.072 178.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.78 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -67.26 132.2 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 120.856 -1.152 . . . . 0.37 110.849 178.306 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 27' ' ' PHE . . . . . 0.528 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 1.9 t80 -71.22 136.72 48.16 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.959 -1.497 . . . . 1.4 106.959 177.008 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 28' ' ' VAL . . . . . 0.887 ' HB ' HD11 ' A' ' 33' ' ' ILE . 1.5 m -139.11 147.87 24.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.919 -1.113 . . . . 1.43 110.899 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 29' ' ' HIS . . . . . 0.698 ' O ' HD12 ' A' ' 33' ' ' ILE . 15.3 t-160 -134.77 150.6 50.57 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 107.533 -1.284 . . . . 1.24 107.533 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' PHE . . . . . 0.509 ' O ' ' HG3' ' A' ' 34' ' ' GLN . 38.4 p90 -72.18 22.62 0.05 Allowed 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.938 -1.101 . . . . 1.47 110.974 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.1 m -113.72 -34.18 5.58 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.815 -1.178 . . . . 1.46 109.625 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.31 -49.87 6.12 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.444 -0.785 . . . . 0.34 109.848 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ILE . . . . . 0.887 HD11 ' HB ' ' A' ' 28' ' ' VAL . 1.3 mt -71.95 -1.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.353 0 O-C-N 121.475 -0.765 . . . . 1.39 109.705 178.922 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLN . . . . . 0.509 ' HG3' ' O ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -67.47 -167.46 0.06 Allowed 'General case' 0 N--CA 1.497 1.883 0 CA-C-O 121.714 0.769 . . . . 3.72 111.735 -178.494 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.5 -168.65 35.56 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.394 -1.482 . . . . 2.74 109.394 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -50.45 118.59 3.12 Favored 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.565 -0.962 . . . . 5.7 110.658 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.69 152.71 24.03 Favored Glycine 0 N--CA 1.499 2.87 0 N-CA-C 110.081 -1.207 . . . . 3.52 110.081 179.452 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -71.12 122.0 19.33 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.368 -1.078 . . . . 5.13 109.05 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.8 mmpp? -112.66 168.55 9.57 Favored 'General case' 0 N--CA 1.501 2.107 0 CA-C-O 122.24 1.019 . . . . 4.96 112.566 -178.559 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' THR . . . . . 0.432 ' C ' ' HG ' ' A' ' 41' ' ' LEU . 1.4 t -143.51 173.53 11.55 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 106.914 -1.513 . . . . 2.9 106.914 177.616 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.604 HD13 ' CD2' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -150.91 164.48 36.22 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.65 -1.281 . . . . 3.8 112.29 -178.294 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -120.58 179.37 4.35 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.012 -1.107 . . . . 3.69 108.012 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.0 tm-20 -73.5 147.2 44.28 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.089 -1.007 . . . . 3.92 108.496 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 95.36 -1.79 64.75 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 110.481 -1.048 . . . . 1.03 110.481 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' GLN . . . . . 0.504 ' NE2' ' HB3' ' A' ' 41' ' ' LEU . 5.5 tt0 -74.4 118.58 17.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.346 -1.091 . . . . 3.23 110.454 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' ' OE1' ' A' ' 3' ' ' GLU . . . -91.23 130.35 37.12 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.364 -0.976 . . . . 0.57 108.364 178.495 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.646 HG21 HD11 ' A' ' 18' ' ' ILE . 26.8 m -124.61 163.81 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.303 -0.873 . . . . 0.46 110.337 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.3 p -116.1 131.18 57.01 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.003 -0.74 . . . . 0.65 109.003 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 49' ' ' PHE . . . . . 1.019 ' CE1' HD11 ' A' ' 2' ' ' LEU . 17.1 p90 -156.49 -176.82 6.18 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.748 0.785 . . . . 1.18 110.329 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.46 92.91 3.59 Favored 'General case' 0 N--CA 1.486 1.368 0 N-CA-C 109.165 -0.679 . . . . 2.53 109.165 179.254 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ILE . . . . . 0.78 HD11 ' CG2' ' A' ' 26' ' ' VAL . 11.9 mt -61.45 135.53 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 CA-C-O 122.105 0.955 . . . . 1.12 110.468 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 14.6 m -118.88 -174.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 106.984 -1.487 . . . . 0.21 106.984 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -122.64 114.16 20.22 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.136 -0.977 . . . . 2.54 109.39 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.96 175.75 18.3 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.829 -1.309 . . . . 0.38 109.829 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -38.38 -51.6 1.54 Allowed 'General case' 0 N--CA 1.512 2.659 0 N-CA-C 113.354 0.872 . . . . 1.97 113.354 -178.739 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 11.83 2.06 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 119.967 -1.708 . . . . 3.91 112.391 -178.782 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.64 -171.41 19.21 Favored Glycine 0 N--CA 1.501 2.99 0 O-C-N 120.539 -1.351 . . . . 0.38 110.479 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.6 Cg_endo -63.77 139.65 69.96 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 121.888 1.726 . . . . 0.33 110.093 178.829 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 59' ' ' GLN . . . . . 0.528 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.6 mt-30 -156.37 145.61 20.56 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.628 -0.67 . . . . 1.69 111.237 -178.981 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.791 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.16 159.73 27.28 Favored 'General case' 0 N--CA 1.502 2.135 0 N-CA-C 107.544 -1.28 . . . . 0.25 107.544 177.077 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.26 -43.72 0.78 Allowed 'General case' 0 N--CA 1.517 2.882 0 O-C-N 120.743 -1.223 . . . . 0.26 112.567 -176.428 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -121.64 54.78 1.12 Allowed 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 106.695 -1.594 . . . . 2.03 106.695 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' VAL . . . . . 0.858 HG22 ' CB ' ' A' ' 49' ' ' PHE . 11.8 t -70.5 165.37 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.515 -0.766 . . . . 0.25 109.781 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 64' ' ' THR . . . . . 0.455 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -154.18 146.85 24.2 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.466 -0.939 . . . . 0.49 108.466 178.518 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 65' ' ' LYS . . . . . 0.569 ' HA ' HG12 ' A' ' 47' ' ' VAL . 4.0 ptpt -60.83 135.93 57.92 Favored 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.403 -0.811 . . . . 3.46 110.21 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -78.87 124.68 28.47 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.419 -0.801 . . . . 2.38 109.793 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 118.499 -0.762 . . . . 2.59 109.627 179.922 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.492 1.641 0 N-CA-C 109.438 -0.579 . . . . 2.78 109.438 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' LEU . . . . . 1.019 HD11 ' CE1' ' A' ' 49' ' ' PHE . 0.0 OUTLIER -140.78 178.03 7.62 Favored 'General case' 0 N--CA 1.502 2.163 0 O-C-N 121.757 -0.589 . . . . 0.64 110.265 179.786 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' GLU . . . . . 0.533 ' OE1' ' HB1' ' A' ' 46' ' ' ALA . 0.1 OUTLIER -113.79 145.88 40.76 Favored 'General case' 0 N--CA 1.497 1.909 0 O-C-N 121.178 -0.951 . . . . 2.04 110.62 -178.644 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' GLY . . . . . 0.488 ' HA3' ' HE2' ' A' ' 49' ' ' PHE . . . -123.63 163.74 17.08 Favored Glycine 0 N--CA 1.497 2.714 0 N-CA-C 109.821 -1.312 . . . . 0.37 109.821 179.69 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' LYS . . . . . . . . . . . . . 84.7 mttt -137.06 124.62 22.2 Favored 'General case' 0 N--CA 1.499 2.025 0 O-C-N 121.377 -1.073 . . . . 2.62 109.543 179.659 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.538 HG13 ' N ' ' A' ' 8' ' ' TRP . 2.7 t -46.29 135.33 2.66 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.356 0 CA-C-O 122.5 1.143 . . . . 0.4 113.597 -179.72 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -94.55 -32.94 13.24 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 103.66 -2.718 . . . . 1.93 103.66 172.413 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' TRP . . . . . 0.639 ' HZ3' ' HB2' ' A' ' 10' ' ' ASN . 24.2 p-90 177.45 148.76 0.15 Allowed 'General case' 0 N--CA 1.488 1.475 0 N-CA-C 106.521 -1.659 . . . . 0.38 106.521 177.734 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' PHE . . . . . 0.604 ' CD2' HD13 ' A' ' 41' ' ' LEU . 0.5 OUTLIER -120.1 143.42 48.15 Favored 'General case' 0 N--CA 1.506 2.368 0 O-C-N 120.629 -1.295 . . . . 1.52 109.745 178.976 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' ASN . . . . . 0.639 ' HB2' ' HZ3' ' A' ' 8' ' ' TRP . 3.8 m-20 -127.17 45.42 2.71 Favored 'General case' 0 N--CA 1.492 1.675 0 N-CA-C 107.042 -1.466 . . . . 1.72 107.042 178.946 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' SER . . . . . . . . . . . . . 33.4 p -45.55 -46.25 13.98 Favored 'General case' 0 N--CA 1.5 2.074 0 CA-C-N 115.861 -0.609 . . . . 1.07 109.808 -178.832 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLU . . . . . . . . . . . . . 1.1 mm-40 -60.54 -45.29 94.44 Favored 'General case' 0 N--CA 1.501 2.104 0 O-C-N 121.775 -0.578 . . . . 2.08 109.791 179.375 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' LYS . . . . . 0.546 ' HB2' ' HB3' ' A' ' 10' ' ' ASN . 7.9 mptt -70.75 -1.2 10.72 Favored 'General case' 0 N--CA 1.501 2.083 0 O-C-N 121.883 -0.511 . . . . 1.51 110.612 179.613 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLY . . . . . 0.467 ' O ' ' HB3' ' A' ' 15' ' ' PHE . . . 93.72 20.28 32.05 Favored Glycine 0 N--CA 1.497 2.739 0 O-C-N 121.212 -0.93 . . . . 0.49 113.049 178.174 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.524 ' HE1' ' HB3' ' A' ' 13' ' ' LYS . 0.4 OUTLIER 178.17 159.9 0.53 Allowed 'General case' 0 N--CA 1.514 2.725 0 CA-C-N 120.318 2.059 . . . . 1.55 112.161 179.457 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.592 ' O ' HG22 ' A' ' 28' ' ' VAL . . . -143.56 154.19 25.37 Favored Glycine 0 N--CA 1.505 3.262 0 N-CA-C 108.236 -1.946 . . . . 0.27 108.236 179.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PHE . . . . . 0.511 ' HB2' ' CE2' ' A' ' 8' ' ' TRP . 4.1 m-85 -115.89 138.46 51.15 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.29 -1.712 . . . . 1.29 110.253 -179.635 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.717 HD12 ' CG1' ' A' ' 28' ' ' VAL . 1.6 mt -106.49 153.98 7.65 Favored 'Isoleucine or valine' 0 N--CA 1.5 2.051 0 N-CA-C 106.872 -1.529 . . . . 0.3 106.872 178.231 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' GLU . . . . . 0.496 ' HA ' ' HA ' ' A' ' 25' ' ' ASP . 12.7 tt0 -127.92 134.17 49.31 Favored 'General case' 0 C--N 1.296 -1.735 0 N-CA-C 108.22 -1.03 . . . . 1.97 108.22 177.95 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' VAL . . . . . 0.601 HG13 ' HB2' ' A' ' 23' ' ' GLN . 9.0 p -136.06 140.15 44.47 Favored 'Isoleucine or valine' 0 N--CA 1.502 2.136 0 C-N-CA 118.185 -1.406 . . . . 0.32 112.029 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 38.3 mt-10 -63.73 137.45 58.07 Favored 'General case' 0 N--CA 1.498 1.946 0 CA-C-N 115.136 -0.938 . . . . 2.71 109.647 179.775 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLY . . . . . . . . . . . . . . . 87.2 -18.34 37.29 Favored Glycine 0 N--CA 1.493 2.442 0 N-CA-C 109.302 -1.519 . . . . 0.42 109.302 -178.756 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' GLN . . . . . 0.601 ' HB2' HG13 ' A' ' 20' ' ' VAL . 0.0 OUTLIER -132.95 -172.86 3.03 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.639 -0.918 . . . . 2.21 108.788 179.586 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' ASP . . . . . . . . . . . . . 0.2 OUTLIER -100.59 -166.95 1.37 Allowed 'General case' 0 N--CA 1.491 1.592 0 CA-C-O 122.07 0.938 . . . . 1.61 110.802 -179.21 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.513 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 2.8 p-10 -73.32 107.19 5.49 Favored 'General case' 0 N--CA 1.491 1.623 0 CA-C-N 115.668 -0.696 . . . . 2.2 110.072 178.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.78 ' CG2' HD11 ' A' ' 51' ' ' ILE . 2.4 t -67.26 132.2 32.51 Favored 'Isoleucine or valine' 0 N--CA 1.503 2.181 0 O-C-N 120.856 -1.152 . . . . 0.37 110.849 178.306 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' PHE . . . . . 0.528 ' HB3' ' HG2' ' A' ' 59' ' ' GLN . 1.9 t80 -71.22 136.72 48.16 Favored 'General case' 0 N--CA 1.493 1.695 0 N-CA-C 106.959 -1.497 . . . . 1.4 106.959 177.008 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' VAL . . . . . 0.887 ' HB ' HD11 ' A' ' 33' ' ' ILE . 1.5 m -139.11 147.87 24.31 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.455 0 O-C-N 120.919 -1.113 . . . . 1.43 110.899 -178.43 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' HIS . . . . . 0.698 ' O ' HD12 ' A' ' 33' ' ' ILE . 15.3 t-160 -134.77 150.6 50.57 Favored 'General case' 0 N--CA 1.488 1.457 0 N-CA-C 107.533 -1.284 . . . . 1.24 107.533 178.803 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' PHE . . . . . 0.509 ' O ' ' HG3' ' A' ' 34' ' ' GLN . 38.4 p90 -72.18 22.62 0.05 Allowed 'General case' 0 N--CA 1.503 2.21 0 O-C-N 120.938 -1.101 . . . . 1.47 110.974 179.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' SER . . . . . . . . . . . . . 1.1 m -113.72 -34.18 5.58 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 120.815 -1.178 . . . . 1.46 109.625 179.386 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ALA . . . . . 0.659 ' HB1' ' O ' ' A' ' 61' ' ' ALA . . . -91.31 -49.87 6.12 Favored 'General case' 0 N--CA 1.5 2.071 0 O-C-N 121.444 -0.785 . . . . 0.34 109.848 -179.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ILE . . . . . 0.887 HD11 ' HB ' ' A' ' 28' ' ' VAL . 1.3 mt -71.95 -1.24 2.21 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.353 0 O-C-N 121.475 -0.765 . . . . 1.39 109.705 178.922 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLN . . . . . 0.509 ' HG3' ' O ' ' A' ' 30' ' ' PHE . 0.0 OUTLIER -67.47 -167.46 0.06 Allowed 'General case' 0 N--CA 1.497 1.883 0 CA-C-O 121.714 0.769 . . . . 3.72 111.735 -178.494 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' GLY . . . . . . . . . . . . . . . -174.5 -168.65 35.56 Favored Glycine 0 N--CA 1.495 2.606 0 N-CA-C 109.394 -1.482 . . . . 2.74 109.394 -179.51 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' GLU . . . . . . . . . . . . . 12.7 mt-10 -50.45 118.59 3.12 Favored 'General case' 0 N--CA 1.507 2.403 0 O-C-N 121.565 -0.962 . . . . 5.7 110.658 -179.58 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . 87.69 152.71 24.03 Favored Glycine 0 N--CA 1.499 2.87 0 N-CA-C 110.081 -1.207 . . . . 3.52 110.081 179.452 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' PHE . . . . . . . . . . . . . 5.6 t80 -71.12 122.0 19.33 Favored 'General case' 0 N--CA 1.5 2.053 0 O-C-N 121.368 -1.078 . . . . 5.13 109.05 179.767 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LYS . . . . . . . . . . . . . 4.8 mmpp? -112.66 168.55 9.57 Favored 'General case' 0 N--CA 1.501 2.107 0 CA-C-O 122.24 1.019 . . . . 4.96 112.566 -178.559 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' THR . . . . . 0.432 ' C ' ' HG ' ' A' ' 41' ' ' LEU . 1.4 t -143.51 173.53 11.55 Favored 'General case' 0 N--CA 1.501 2.075 0 N-CA-C 106.914 -1.513 . . . . 2.9 106.914 177.616 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.604 HD13 ' CD2' ' A' ' 9' ' ' PHE . 0.0 OUTLIER -150.91 164.48 36.22 Favored 'General case' 0 N--CA 1.502 2.165 0 O-C-N 120.65 -1.281 . . . . 3.8 112.29 -178.294 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' GLU . . . . . . . . . . . . . 2.3 mt-10 -120.58 179.37 4.35 Favored 'General case' 0 N--CA 1.495 1.797 0 N-CA-C 108.012 -1.107 . . . . 3.69 108.012 178.496 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' GLU . . . . . . . . . . . . . 5.0 tm-20 -73.5 147.2 44.28 Favored 'General case' 0 N--CA 1.497 1.892 0 O-C-N 121.089 -1.007 . . . . 3.92 108.496 179.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 95.36 -1.79 64.75 Favored Glycine 0 N--CA 1.493 2.477 0 N-CA-C 110.481 -1.048 . . . . 1.03 110.481 -179.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' GLN . . . . . 0.493 ' CD ' ' HB3' ' A' ' 41' ' ' LEU . 22.6 tt0 -74.4 118.58 17.52 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.346 -1.091 . . . . 3.23 110.454 -179.487 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.533 ' HB1' ' OE1' ' A' ' 3' ' ' GLU . . . -91.23 130.35 37.12 Favored 'General case' 0 N--CA 1.492 1.667 0 N-CA-C 108.364 -0.976 . . . . 0.57 108.364 178.495 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.646 HG21 HD11 ' A' ' 18' ' ' ILE . 26.8 m -124.61 163.81 24.2 Favored 'Isoleucine or valine' 0 N--CA 1.501 2.102 0 O-C-N 121.303 -0.873 . . . . 0.46 110.337 -179.402 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' SER . . . . . . . . . . . . . 37.3 p -116.1 131.18 57.01 Favored 'General case' 0 N--CA 1.495 1.819 0 N-CA-C 109.003 -0.74 . . . . 0.65 109.003 179.823 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' PHE . . . . . 1.019 ' CE1' HD11 ' A' ' 2' ' ' LEU . 17.1 p90 -156.49 -176.82 6.18 Favored 'General case' 0 N--CA 1.499 1.992 0 CA-C-O 121.748 0.785 . . . . 1.18 110.329 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' GLU . . . . . . . . . . . . . 1.3 tt0 -127.46 92.91 3.59 Favored 'General case' 0 N--CA 1.486 1.368 0 N-CA-C 109.165 -0.679 . . . . 2.53 109.165 179.254 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ILE . . . . . 0.78 HD11 ' CG2' ' A' ' 26' ' ' VAL . 11.9 mt -61.45 135.53 26.02 Favored 'Isoleucine or valine' 0 N--CA 1.499 2.023 0 CA-C-O 122.105 0.955 . . . . 1.12 110.468 -179.573 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' VAL . . . . . 0.59 ' O ' ' HA ' ' A' ' 58' ' ' PRO . 14.6 m -118.88 -174.46 0.8 Allowed 'Isoleucine or valine' 0 N--CA 1.485 1.283 0 N-CA-C 106.984 -1.487 . . . . 0.21 106.984 179.05 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLU . . . . . . . . . . . . . 21.0 mt-10 -122.64 114.16 20.22 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.136 -0.977 . . . . 2.54 109.39 179.857 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' GLY . . . . . . . . . . . . . . . -127.96 175.75 18.3 Favored Glycine 0 N--CA 1.496 2.649 0 N-CA-C 109.829 -1.309 . . . . 0.38 109.829 179.999 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ASN . . . . . . . . . . . . . 0.5 OUTLIER -38.38 -51.6 1.54 Allowed 'General case' 0 N--CA 1.512 2.659 0 N-CA-C 113.354 0.872 . . . . 1.97 113.354 -178.739 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -77.96 11.83 2.06 Favored 'General case' 0 N--CA 1.505 2.309 0 O-C-N 119.967 -1.708 . . . . 3.91 112.391 -178.782 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' GLY . . . . . . . . . . . . . . . 104.64 -171.41 19.21 Favored Glycine 0 N--CA 1.501 2.99 0 O-C-N 120.539 -1.351 . . . . 0.38 110.479 179.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' PRO . . . . . 0.59 ' HA ' ' O ' ' A' ' 52' ' ' VAL . 1.6 Cg_endo -63.77 139.65 69.96 Favored 'Trans proline' 0 CA--C 1.539 0.774 0 C-N-CA 121.888 1.726 . . . . 0.33 110.093 178.829 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' GLN . . . . . 0.528 ' HG2' ' HB3' ' A' ' 27' ' ' PHE . 2.6 mt-30 -156.37 145.61 20.56 Favored 'General case' 0 N--CA 1.505 2.323 0 O-C-N 121.628 -0.67 . . . . 1.69 111.237 -178.981 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.791 ' HB1' HG22 ' A' ' 63' ' ' VAL . . . -79.16 159.73 27.28 Favored 'General case' 0 N--CA 1.502 2.135 0 N-CA-C 107.544 -1.28 . . . . 0.25 107.544 177.077 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' ALA . . . . . 0.659 ' O ' ' HB1' ' A' ' 32' ' ' ALA . . . -134.26 -43.72 0.78 Allowed 'General case' 0 N--CA 1.517 2.882 0 O-C-N 120.743 -1.223 . . . . 0.26 112.567 -176.428 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' ASN . . . . . . . . . . . . . 1.7 m-20 -121.64 54.78 1.12 Allowed 'General case' 0 C--N 1.293 -1.853 0 N-CA-C 106.695 -1.594 . . . . 2.03 106.695 -179.723 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' VAL . . . . . 0.858 HG22 ' CB ' ' A' ' 49' ' ' PHE . 11.8 t -70.5 165.37 2.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 CA-C-N 115.515 -0.766 . . . . 0.25 109.781 -178.983 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' THR . . . . . 0.455 ' N ' HG12 ' A' ' 63' ' ' VAL . 0.2 OUTLIER -154.18 146.85 24.2 Favored 'General case' 0 N--CA 1.497 1.876 0 N-CA-C 108.466 -0.939 . . . . 0.49 108.466 178.518 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' LYS . . . . . 0.569 ' HA ' HG12 ' A' ' 47' ' ' VAL . 4.0 ptpt -60.83 135.93 57.92 Favored 'General case' 0 N--CA 1.505 2.28 0 O-C-N 121.403 -0.811 . . . . 3.46 110.21 -179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -78.87 124.68 28.47 Favored 'General case' 0 N--CA 1.497 1.907 0 O-C-N 121.419 -0.801 . . . . 2.38 109.793 -179.901 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.497 1.889 0 CA-C-O 118.499 -0.762 . . . . 2.59 109.627 179.922 . . . . . . . . 0 0 . 1 stop_ save_